CONFLICT OF INTEREST STATEMENT
Cancer, Novocure
CANCER
E. Gabriela Chiorean reports personal fees from AstraZeneca, Bayer, Celgene, Eisai, Ipsen, Legend, Merck, Novartis, Noxxon, Pfizer, Seattle Genetics, Sobi, and Stemline, and grants from Boehringer–Ingelheim, Bristol–Myers Squibb, Celgene, Clovis, Corcept, Fibrogen, Halozyme, Incyte, Lonza, Lilly, MacroGenics, Merck, Rafael, Roche, and Stemline. V. Picozzi reports research funding from Abbvie, FibroGen, Ipsen, Merus, NGM Biopharmaceuticals, and Novocure and a consulting or advisory role with TriSalus Life Sciences, and stock and other ownership interests with Amgen and Johnson & Johnson. C‐P. Li reports no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. M. Peeters reports no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. J. Maurel reports research funding from Carlos III Health Institute; Catalan Agency for Management of University and Research Grants; Fundació la Marató de TV3; Olga Torres Foundation, and a consulting or advisory role with Advance Medical; Amgen; AstraZeneca; Bayer; Biocartis; Cancer Expert Now; Fundación Clínica Universitaria; Incyte; Merck; NanoString Technologies; Pierre Fabre; Roche; Sanofi; SERVIER; Shire; Sirtex Medical. J. Singh reports no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. T. Golan reports honoraria from MSD, consulting or advisory roles with Abbvie, AstraZeneca, MSD, and Teva, speakers' bureau from Abbvie, AstraZeneca, and institute research funding from AstraZeneca and MSD. J‐F. Blanc reports consulting or advisory roles for Bayer, Ipsen, Eisai, Bristol–Myers Squibb, Roche and AstraZeneca, Servier, Incyte. S. C. Chapman, A. M. Hussain, and E. L. Johnston are full‐time employees of Eli Lilly and Company and are Eli Lilly and Company shareholders. H. Hochster reports personal fees from Bayer and Genentech and personal fees and nonfinancial support from Elion and TRIGR.